



(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/485 (2006.01)
A61K 45/06 (2006.01) A61P 1/10 (2006.01)

(21) International Application Number:

PCT/US2023/064088

(22) International Filing Date:

10 March 2023 (10.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/318,465 10 March 2022 (10.03.2022) US

(71) Applicant: **GLYCYX MOR INC.** [US/US]; 5654 Geary Blvd. #210181, San Francisco, California 94121 (US).

(72) Inventors: **JOHNSON, Lorin**; 27001 Appaloosa Way, Los Altos Hills, California 94022 (US). **MOSS, Jonathan**; 270 E. Pearson Street, Apartment 1101, Chicago, Illinois 60611 (US). **TAGGART, David**; 1724 N. Craigton Court, Tucson, Arizona 85715 (US).

(74) Agent: **KLECYNGIER, David** et al.; BakerHostetler, 1050 Connecticut Ave, N.W., Suite 1100, Washington, District of Columbia 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST




FIG. 1B

(57) Abstract: Provided herein are compositions and methods of using a Mu opioid receptor (MOR) antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor (such as e.g. an inhibitor of the PD-1/PD-L1 pathway (e.g. an antibody such e.g. pembrolizumab)) and/or an inhibitor of VEGF (e.g. bevacizumab) for reducing angiogenesis or treating cancer. Also provided herein are kits containing a MOR antagonist (e.g. axelopran) alone or in combination with checkpoint inhibitor and/or an inhibitor of VEGF for reducing angiogenesis or treating cancer.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

19 October 2023 (19.10.2023)